Purple Biotech Announces Plan to Implement ADS Ratio Change
Purple Biotech Ltd. - American Depositary Shares (PPBT)
Company Research
Source: GlobeNewswire
ADS Will Begin Trading Reflecting the Ratio Change on March 2, 2026 REHOVOT, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity, today announced that it intends to change the ratio of American Depositary Shares (“ADSs”) to its ordinary shares, no par value per share (the “ADS Ratio”), from the current ADS Ratio of one (1) ADS representing two hundred (200) ordinary shares, to a new ADS Ratio of one (1) ADS representing two thousand (2,000) ordinary shares (the “ADS Ratio Change”). The ADS Ratio Change is expected to become effective at the beginning of trading on or about March 2, 2026, U.S. Eastern Time (the “Effective Date”). The primary purpose of the ADS Ratio Change is to enable the Company to regain compliance with the $1.00 minimum bid price requirement for continued
Show less
Read more
Impact Snapshot
Event Time:
PPBT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PPBT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PPBT alerts
High impacting Purple Biotech Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
PPBT
News
- Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240GlobeNewswire
- Purple Biotech (NASDAQ:PPBT) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Purple Biotech Reports Positive New Preclinical Data Demonstrating Multi-Arm Anti-Tumor Activity Across Two CAPTN-3 Tri-Specific Antibodies at ESMO Immuno-Oncology Congress 2025GlobeNewswire
PPBT
Sec Filings
- 2/25/26 - Form 6-K
- 2/20/26 - Form 424B3
- 2/13/26 - Form SCHEDULE
- PPBT's page on the SEC website